Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 16/20 | 0.71 |
| ▸ | MMP2 | P08253 | 8/20 | 0.71 |
| ▸ | MMP9 | P14780 | 6/20 | 0.71 |
| ▸ | MMP3 | P08254 | 5/20 | 0.71 |
| ▸ | MMP8 | P22894 | 4/20 | 0.71 |
| ▸ | MMP7 | P09237 | 3/20 | 0.71 |
| ▸ | FCER2 | P06734 | 3/20 | 0.71 |
| ▸ | MMP12 | P39900 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7616099 | 0.89 | MMP1 (0.73) | MMP1MMP2MMP9MMP3MMP8 | |
| SCHEMBL6434826 | 0.88 | MMP2 (0.73) | MMP1MMP2MMP9MMP3MMP8 | |
| SCHEMBL4670160 | 0.87 | MMP1 (0.78) | MMP1MMP2MMP9MMP3MMP8 | |
| SCHEMBL5099222 | 0.86 | MMP2 (0.80) | MMP1MMP2MMP9MMP3MMP8 | |
| SCHEMBL5502507 | 0.83 | MMP2 (1.00) | MMP1MMP2MMP9MMP3MMP8 | |
| SCHEMBL10633276 | 0.81 | MMP1 (0.65) | MMP1MMP2MMP9MMP3MMP8 | |
| SCHEMBL7330972 | 0.81 | MMP1 (0.66) | MMP1MMP2MMP9MMP3MMP8 | |
| SCHEMBL7330965 | 0.81 | MMP1 (0.66) | MMP1MMP2MMP9MMP3MMP8 | |
| SCHEMBL28221967 | 0.81 | MMP1 (0.66) | MMP1MMP2MMP9MMP3MMP8 | |
| SCHEMBL6577614 | 0.81 | MMP2 (0.80) | MMP1MMP2MMP9MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082200-A1 | Use of inhibitors of human S-CD23 | SMITHKLINE BEECHAM P.1.C. | 2002-06-27 | — | — | US | claimed |
| US-20020082200-A1 | Use of inhibitors of human S-CD23 | SMITHKLINE BEECHAM P.1.C. | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082200-A1 | Use of inhibitors of human S-CD23 | TIMP3, MMP3, MMP13 | MMP1 7/4885MMP2 10/4885MMP9 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.